Amyotrophic lateral sclerosis (ALS) is a devastating, incurable neurodegenerative disease that affects upper and lower motor neurons and that affects approximately 3 in every 100,000 adults in the United States, most commonly between the ages of 40 and 70 years. Degeneration of motor neurons leads to loss of motor control and strength (which affects the limbs, speech, swallowing, and respiration) and ultimately to the need for permanent respiratory support or death. The majority of patients with ALS die within 3-5 years after disease diagnosis.
Currently, the only approved medication for the treatment of ALS is riluzole, which has only a modest survival benefit and no functional benefit. Thus, there remains significant interest in additional approaches that may slow the rate of motor neuron degeneration and provide benefit to patients with ALS.
NOCCR Knoxville is currently enrolling volunteers age 18 or older with ALS for a clinical trial testing a medication in development for the treatment of ALS.
Volunteers must be willing to stay overnight in the study center on five separate occasions for 5 days and 4 nights each, and complete 10 follow up visits. Compensation is available for time and travel.
To learn if you might qualify, please complete the questionnaire for this study or contact a member of our recruitment team at 865-305-DRUG(3784).